Imagine a world where there is no donor organ shortage, victims of spinal cord injuries can walk and weakened hearts are successfully replaced; this is the future of regenerative medicine, as outlined by the National Institute of Health. To obtain the massive promises of this revolutionary treatment option, however, it is necessary to successfully overcome the barriers associated with immune response, which have, to this point, severely hampered the advancement of cell replacement therapies. International Stem Cell Corporation (OTCQB: ISCO), through the continued development of its groundbreaking parthenogenesis stem cell technology, is addressing this limitation, potentially unlocking the door to significant advances in the field of regenerative medicine.

Parthenogenesis utilizes unfertilized human eggs to create pluripotent parthogenetic stem cells (hpSC) that can be immune-matched to millions of people. According to the company’s data, a relatively small number of hpSC lines could provide sufficient immune-matched cells to cover a large percentage of the world’s population, effectively minimizing the effects of autoimmune rejection and allowing for continued research into the massive potential upside of stem cell therapy. Unlike embryonic stem cells, which require the destruction of a human embryo, hpSC treatment also avoids many of the ethical issues commonly associated with stem cell research.

ISCO has identified a collection of potential diseases and conditions that could be effectively treated using its hpSCs, but the company’s leading indication is for the treatment of Parkinson’s disease. According to the National Parkinson Foundation, Parkinson’s disease is the 14th leading cause of death in the United States, and an estimated four to six million people suffer from the condition worldwide. Currently, there is no cure and limited treatment options for the disease, creating a significantly underserved market within the pharmaceutical industry.

“In the first quarter of 2015 we completed all the necessary preclinical studies of our Parkinson’s program and formally submitted our application to begin the first clinical study of this novel approach to treating this debilitating disease in humans,” stated Dr. Andrey Semechkin, Chief Executive Officer of ISCO. “We continue to expect to make significant progress during the rest of 2015 towards our goal of providing a viable treatment option for people with Parkinson’s disease.”

During preclinical studies, ISCO has demonstrated the safety and efficacy of treating Parkinson’s disease symptoms in animals with transplanted human parthenogenetic neural stem cells. Moving forward, the company will seek to begin its Phase I/IIa clinical studies through its wholly-owned subsidiary, Cyto Therapeutics Pty Ltd. For prospective shareholders, ISCO’s continued progression with preclinical and clinical studies makes the company an intriguing investment opportunity in the months to come.

For more information, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

Dominovas Energy’s stock had an impressive run earlier this week after the fuel cell technology company announced a “historic” partnership with the U.S. Government. Shares soared nearly 3000% on the news, hitting an intra-week high of $0.33; the stock trades in a 52-week range of $0.0035-$0.60. A federal partnership is obviously a big deal and warrants a look at how this micro-cap company got its name on the books.

More than ever before, consumers are spending their money on “green” alternatives, tuning into global concerns about climate change, energy security, and air pollution. Dominovas Energy looks at these issues on a global scale, as it seeks to implement its fuel cell technology in emerging countries, where reliable electricity is intermittent, scarce, or non-existent.

Focusing on this global concern, Dominovas Energy is committed to creating a virtually silent solution with near-zero NOX emissions and minimal carbon footprint, all while producing reliable and clean energy for local communities, industry, and nations. To this accord, Dominovas Energy is championing its RUBICON™ Solid Oxide Fuel Cell (SOFC) system as a leading, viable, global energy solution.

Fuel cell power generation is an efficient, combustion-less, reliable and virtually pollution-free emitting device that provides electricity to power a wide array of applications, ranging from buildings, primary power for grid integration, automobiles, emergency back-up systems, and base load grid power. By electrochemically combining oxygen with hydrogen extracted from a hydrocarbon-based fuel supply to produce electricity, emitting only water, minimal pollution, and excess heat as by-products, fuel cells function much like a battery, but without the need for recharging. Fuel cells produce electricity as long as there is a constant fuel source and are rapidly gaining traction as an ideal solution for a variety of portable, on-board, and stationary electric power generation applications.

Dominovas Energy has identified marketing and sales opportunities for fuel cells in emerging-market countries, where electricity supply is frequently unreliable, antiquated, and expensive compared to the cost of electricity and the production, as found in the United States. Consequently, the Company’s primary focus at this time is on Africa, where it has established active projects and works with each nation’s government. And further with the support of Delphi Automotive Systems to jointly develop the technology and methodologies necessary to facilitate the commercial nature, manufacture, assembly, and deployment of the RUBICON™ system, this partnership fully supports Dominovas Energy’s continued deployment of clean energy solutions on a multi-megawatt (MW) scale.

As detailed in an historic announcement in June, Dominovas Energy was accepted as a private sector partner of the “Power Africa Initiative” launched by President Barack Obama in June 2013. A multi-year guaranteed power provider agreement (PPA) announced earlier this month shows how Dominovas Energy jumped into action in Africa.

At the beginning of June, Dominovas Energy reported that it signed a 3MW PPA to utilize the RUBICON™ system to provide clean electricity to the City of David in the Democratic Republic of the Congo (DRC). Expected to be “the first of many efforts the governor of the State of Katanga in the Democratic Republic of Congo is pursuing across his state to increase the availability of affordable housing and social facilities,” the Project will represent the largest single deployment of fuel cell technology on the continent of Africa.

Slated for the fourth quarter of 2016, the physical deployment of the RUBICON™ will trigger the annual production of more than 25.5 million kWh of clean, efficient and reliable electricity and will yield more than US$100 million in guaranteed revenue to Dominovas Energy over the course of the agreement.

A week after the City of David announcement, Dominovas Energy signed another 3MW multi-year PPA. This time the agreement concerned Dominovas providing electricity to the privately held Somico Mine in the DRC. Somico has several mining operations in the DRC; and with the vast reserves of natural resources in Africa, the mining sector represents a tremendous opportunity for Dominovas Energy’s continued expansion across diverse applications of the RUBICON™. The mining sector in Africa singularly represents a multibillion dollar industry, and offers Dominovas Energy the potential to deploy more than 250 MW of power to mining operations and their communities.

Now fast-forward to date – and take a look at how Dominovas Energy pivoted from the PPAs to its deal with the U.S. government.

By deploying its RUBICON™ systems, Dominovas Energy is the first-and-only fuel cell company selected as a private sector partner to the Power Africa Initiative, which is comprised of private sector participants, the United States government and governments of several African countries. These partners represent the foundation for building the regulatory, economic, and policy framework needed to meet Africa’s increasing demand for, and access to, electricity.

As a Power Africa member company, Dominovas Energy will benefit from interagency efforts, leveraging Power Africa’s tools such as technical expertise and financing. Dominovas said that over the next several years, it intends to support and advance Power Africa goals by providing access to clean, reliable energy; partnering with specific universities in Africa to train and hire local citizens as engineers and technicians, as necessary for the installation, service, and ongoing maintenance of the RUBICON™; and providing Power Africa countries with access to distributed, off-grid electricity on a multi-megawatt scale.

According to the Company’s news release, deployments of the RUBICON™ are expected to increase the quantity of power available to over 100 million people by 2021, directly benefitting citizens, households, and businesses by producing clean, reliable and continuous energy.

When you look at the broader Dominovas Energy picture, take into consideration that financials are not typically stellar at the sub-penny level DNRG was trading at last week; but deals like the ones mentioned above, solid operations, and a powerful management team are what give small companies a tangible base from which to realize its strong potential and validate its place on the map.

Neal Allen is chairman, president and CEO of Dominovas Energy. He previously served in the same capacity with Dominovas Energy, LLC. Prior to Dominovas Energy, LLC he served as the Principal Shareholder of a private Family Office, which specialized in the development and implementation of proprietary revenue models as a force multiplier ensuring optimal deployment, utilization, and management of financial resources. Under Allen’s watch, the Family Office’s endeavors included the ownership of a “major brand” automobile dealership, several healthcare companies, waste management and disposal enterprises, land acquisition and development, and natural resource development enterprises.

Allen is joined by Emilio De Jesus, board member and president of the Africa Division for Dominovas, where he is integral in assisting in the creating of strategies that best bring to fruition the deployment of the RUBICON™ to emerging markets in Africa.

De Jesus specializes in intelligence pertaining to each country’s barriers of entry, political climate and most suitable partners. As the Country Advisor, De Jesus visits potential countries to research their state of the energy production industry, interview potential partners, and meet with political officials. He also negotiates favorable PPAs, liaising with local partners, as well as with potential “Off Takers.”

De Jesus, for over 15 years, previously managed telecommunications projects for a fortune 500 company, and has gained extensive experience in the deployment of new technologies within Continental USA.

Piece by piece, the Dominovas Energy story makes sense – portraying the Company’s momentum as it achieves its commitment to emerging markets and solidifies its position in the United States as a viable ally to Africa and its long-term power needs. The Company has a keen ability to recognize and take advantage of the incredible growth and profit opportunities of the green and alternative energy markets, advancing the deployment of its green energy solutions where it matters most.

For more information visit www.dominovasenergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

Today, The One World Doll Project, a subsidiary of One World Holdings, reported an initial order from Hallmark Stores for the Prettie Girls!(TM) Tween Scene multicultural fashion and play dolls. This order resulted from a preliminary outreach to the company by the Hallmark buying team. The placement of these dolls within Hallmark Stores across the country will bring additional exposure to the Prettie Girls! brand.

“As we continue to see a significant increase in product sales, this new business relationship with Hallmark Stores represents another component of our 2015 growth plan,” stated Trey Waldhauser, VP of Sales at The One World Doll Project.

Established in 2010 to make a significant positive cultural impact through the doll category, The One World Doll Project aims to transcend global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.

For more information on the company, visit www.oneworlddolls.com

Let us hear your thoughts: One World Holdings Message Board

On the Move Systems specializes in the development of cutting-edge technology to transform and synchronize freight supply chain operations for a broad range of industries. The company is exploring new online tools to reduce costs and increase convenience in the tourism and travel industry, as well as new opportunities in trucking. OMVS works with a premier group of international providers to offer its services in two key divisions: Trucking Logistics and Inter-modal Freight.

Logistics are critical to the success of any operation. OMVS’s Trucking Logistics division operates as one of the most competitive, full-service transportation logistics providers in the United States. Utilizing the company’s ISTx Platform, this division helps customers strategize how to get from one point to another, as well as solves some of the toughest logistics challenges on the road today. OMVS’s Trucking Logistics technology provides customers increased visibility, minimal-cost route effectiveness, and delivery assurance.

OMVS’s Intermodal Freight division offers seamless cargo continuation, tracking, shipping and receiving of goods anywhere in the world. The company’s customer service teams and drivers communicate through the ISTx Platform allowing for flexibility, control and monitoring of each freight shipment. OMVS continues to research and explore the most effective and resourceful tools in order to effectively serve customers with unique shipping requirements in the billion dollar trucking industry.

In his more than 20 years of experience, OMVS president and CEO Robert Wilson has cultivated vast expertise as an executive and financial consultant for companies in aviation, energy, oil and gas, IT and healthcare. In addition to his work valuing and assessing small-to-middle market companies, Wilson has also served as both an officer and director of such client companies. Wilson applies his expertise in the transportation business and investment banking to spearhead OMVS’s new initiative to create a new kind of online transportation platform to an international market.

For more information, visit www.onthemovesystems.com

Let us hear your thoughts: On the Move Systems Corp. Message Board

Earlier this morning, Net Element announced that PayOnline signed a new 3-year contract to process transactions for certain international dating networks, including AnastasiaDate, AmoLatina and AsianDate. Collectively, these networks receive more than 150 million unique visits annually and have more than 4 million registered users that spend more than 360 million hours on the sites per year.

Net Element currently manages, operates and is in the process of integrating the PayOnline group of companies pending closing of its previously announced acquisition initiative.

The contract with the majority owner of the dating networks, Social Discovery Ventures (“SDV”), is expected to achieve minimum net revenues to Net Element in the amount of $1.2 million over 3 years and a minimum transaction processing commitment of $300 million.

The contract underscores Net Element’s advantage as a global payments-as-a-service platform that facilitates cross-border transactions yet on-boards through a single interface.

SDV’s dating networks will use PayOnline’s state-of-the-art global online payments gateway and fraud-management tools to manage its international online transaction processing.

“The millions of international users on our premium dating networks require a reliable service able to process high volume, cross-border transactions using all forms of payments,” stated Anthony Volpe, Social Discovery Ventures chief marketing officer. “We selected Net Element because they met that need.”

“This contract win demonstrates our ability to quickly derive value from strategic acquisitions and partnerships,” added Oleg Firer, Net Element CEO. “As we emerge from a period of financial and business restructuring, we plan to see more such value driving developments as we progress into our growth phase.”

For more information on Net Element, visit www.netelement.com

IEG Holdings Corp. is a provider of online unsecured consumer loans in 13 states under the ‘Mr. Amazing Loans’ brand. In recent months, the company has leveraged this proven business model to record improved financial results. Since launching its online lending platform in July 2013, IEG has increased its cumulative loan value by well over 3,200 percent, exceeding $8 million in May. This rapid growth is being driven by the company’s continued state licensing expansion, which is expected to include an additional 12 states by the end of 2015, including California and Ohio. Following these efforts, IEG expects its lending coverage to encompass approximately 80 percent of the U.S. population.

In addition to its domestic growth, IEG has recently made strides toward expanding its presence in the global lending market. In December, the company announced the re-launch of lending in Australia under the ‘Mr. Amazing Loans’ brand, as well as detailing plans to add an additional 1.45 billion people to its lending network through a commitment to international development. In particular, IEG has highlighted Canada, United Kingdom, Philippines and India as expansion candidates because of their strong market demand and developed lending industry.

The company’s continued commitment to increasing its market share has provided a platform for tremendous revenue growth in recent quarters. In the first quarter of 2015, IEG recorded interest revenue of nearly $340,000, a year-over-year boost of more than 1,000 percent. Moving forward, this figure is expected to grow significantly in concert with the continued geographical expansion of IEG’s lending services.

In June, IEG took a step toward the future when it upgraded from the OTC market group’s OTC Pink tier to the OTCQB tier. The company will look to build on this progress in the future by potentially uplisting to the NASDAQ Global Markets. IEG announced the submittal of an application for this change in May.

“It is exciting to become an SEC reporting company, continue our rapid expansion… and achieve record loan volumes,” Paul Mathieson, chairman and chief executive officer of IEG, stated in a news release. “By late 2015, we hope to be in a position to offer loans in 25 states, covering approximately 25 million people.”

For prospective shareholders, IEG’s rapid growth since launching its lending platform just under two years ago makes the company an intriguing investment opportunity in the months to come.

For more information, visit www.investmentevolution.com

Synergy Resources Corp. is a domestic oil and natural gas exploration and production company operating in the Wattenberg Field of the Denver-Julesburg Basin in northeast Colorado. The company operates 308 wells throughout the region, in addition to having an ownership interest in nearly 300 net producing wells. Through these projects, Synergy has access to an estimated 40.3 million barrels of oil equivalent, according to a February report by independent oil and gas consulting firm Ryder Scott Company.

The Denver-Julesburg Basin has established itself as one of the most important producing areas in the country by consistently generating oil and gas since its discovery in 1901. The total value of past production from the region, if calculated in modern prices, would exceed $150 billion. For Synergy, the basin’s high level of predictability and high drilling success rate could provide the company with an opportunity to achieve rapid return on investment in the future.

During its fiscal second quarter of 2015, Synergy leveraged its position within the Wattenberg field to dramatically increase production. In addition to increasing year-over-year revenue by three percent, the company recorded a 98 percent year-over-year increase in overall production. Primarily, this spike was a result of Synergy’s December acquisition of a 5,040 acre leasehold in the Wattenberg Field, which provided access to 73 operating vertical wells, as well as non-operated working interests in 17 horizontal wells.

“Our growth in proved reserves is a result of the success of our operated horizontal drilling program, the performance of the horizontal wells in the Wattenberg Field, and proved reserves added as a result of our acquisition we completed in December,” William E. Scaff, co-chief executive officer of Synergy, stated in a news release.

In May, Synergy continued to expand its presence in the Denver-Julesburg Basin when it reached an agreement with its non-operating partner to purchase the remaining 35 percent working interest in the Greenhorn prospect, which is located in the northeast extension area of the basin.

“Over the past twelve months we have been pursuing a higher working interest in all of our operated assets both in the core of the Wattenberg Field and in the extension area,” Scaff continued. “This acquisition… is consistent with that objective.”

Despite a sharp decrease in commodity prices that’s persisted throughout the first six months of 2015, Synergy’s recent performance is a promising indication for prospective investors moving forward. Look for the company to leverage its established position within the Greater Wattenberg Field with the goal of encouraging sustainable returns in the years to come.

For more information, visit www.syrginfo.com

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of products to treat serious and life-threatening diseases. The company’s product pipeline includes two phase III product candidates. The first, Blisibimod, is currently being studied for the treatment of lupus, a chronic disease that causes a patient’s immune system to attack his or her own tissues and organs. The second, Sollpura™, is currently being studied as a novel pancreatic enzyme replacement therapy for the treatment of cystic fibrosis and related diseases.

In recent months, Anthera made major strides toward the eventual commercialization of these two groundbreaking drug candidates. In March, the company secured a research award of up to $3 million from Cystic Fibrosis Foundation Therapeutics, Inc. to support the manufacturing and clinical development of Sollpura.

“Support from Cystic Fibrosis Foundation Therapeutics speaks to the importance of developing [Sollpura] and the organization’s extensive clinical trials network will be indispensable as we advance this therapy,” Paul F. Truex, president and chief executive officer of Anthera, stated in a news release.

Earlier this month, the company made significant progress in the development of Blisibimod by reaching the target enrollment goal for its CHABLIS-SC1 phase III clinical trial. The results from this study, which are expected to be available in the second half of 2016, are anticipated to support the eventual market approval of Blisibimod for the treatment of lupus.

“Reaching our enrollment target for CHABLIS-SC1 ahead of schedule is an important accomplishment,” stated Dr. Colin Hislop, chief medical officer of Anthera. “The accelerated pace speaks to the importance of patient identification and selection in lupus treatment.”

When commercialized, these two products could provide Anthera with a strong platform to realize considerable growth within the biopharmaceutical industry. According to the Lupus Foundation of America, an estimated 1.5 million Americans, and at least five million people worldwide, suffer from some form of Lupus. Likewise, according to the Cystic Fibrosis Foundation, an estimated 30,000 Americans, and approximately 70,000 people worldwide, suffer from cystic fibrosis.

For prospective investors, Anthera’s continued progress toward commercialization of its two unique drug candidates makes the company an intriguing investment opportunity in the months to come.

For more information, visit www.anthera.com

Apollo Medical Holdings (OTC: AMEH) is a leading integrated healthcare company providing solutions to hospitals, health plans, physicians and other health providers that enable cost-effective, quality healthcare. The company utilizes integrated care solutions in order to identify and manage patients who are at-risk for chronic conditions. By coordinating care for these patients across multiple facilities, ApolloMed helps them reduce hospital admissions and avoid unnecessary emergency room visits, providing the means for reduced overall medical costs without sacrificing on quality of care.

Earlier this month, ApolloMed announced that its network of physicians had surpassed 1,000 providers. Through this network, the company is able to provide leading health management services to more than 40,000 of its own patients, as well as over 75,000 additional patients for its clients. The company’s network of dedicated hospitalists, nursing home physicians, clinic physicians, hospice care group and home health agency allow ApolloMed to provide care for some of the most complex and highest cost patients in the United States healthcare system.

Moving forward, ApolloMed is in a strong position to capitalize on the evolving landscape of the medical industry, particularly as it relates to value-based payments. In January, the U.S. Department of Health and Human Services (HHS) announced substantial changes to the way in which Medicare payments will be processed in the future. HHS set a goal of tying 30 percent of fee-for-service Medicare payments to quality or value through alternative payment models by the end of 2016. By the end of 2018, this change is expected to affect at least 50 percent of all Medicare payments. This announcement marked the first time in the history of the Medicare program that explicit goals for value-based payments have been set.

“Over the past three years, we have built a growing, robust network of physicians and an outcome-centric population health management platform that is at the forefront of the movement to value-based care,” Dr. Warren Hosseinion, chief executive officer of ApolloMed, stated in a news release. “We believe ApolloMed is well positioned to benefit from these transformative changes and sizable market growth over the next decade.”

For prospective shareholders, ApolloMed represents an opportunity to invest in an established player in the value-based medical market. With the recently announced shift in Medicare payment processing, the company’s developed and expanding network of medical group and accountable care organization physicians could provide a platform for increased revenues and, as a result, sustainable shareholder returns in the years to come.

For more information, visit www.apollomed.net

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a biotechnology company focused on the development and commercialization of best-in-class pharmaceutical products that address major unmet medical needs. The company’s leading drug candidate, SUSTOL®, is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV), which affects approximately 75 percent of patients undergoing cancer treatment.

SUSTOL improves upon the current treatment options for CINV by utilizing Heron’s proprietary drug delivery platform, Biochronomer®. The company’s groundbreaking delivery technologies allow for sustained levels of drugs in systemic circulation, providing prolonged efficacy in a variety of potential applications. In clinical studies, Heron has demonstrated these benefits, with SUSTOL maintaining therapeutic drug levels for up to five days with a single subcutaneous injection.

In recent months, the company has taken significant steps toward the eventual commercialization of SUSTOL. In May, Heron announced the top-line results from its 900 patient phase III clinical study of the product candidate. According to these results, SUSTOL provided significantly higher rates of complete response than the test’s three-drug standard of care comparator group, demonstrating the overall efficacy and market potential of the candidate.

“[T]he results… further demonstrate the potential for SUSTOL to be the foundation of the new standard-of-care injectable anti-emetic regimen,” Barry D. Quart, chief executive officer of Heron, stated in a news release. “[W]e are planning for the commercial launch of SUSTOL, pending FDA approval.”

In addition to its progress with SUSTOL, Heron has also taken significant steps in the development of its second drug candidate, HTX-011, in recent weeks. Earlier this month, the company announced the initiation of a phase II clinical trial on the candidate for the prevention of post-operative pain. By effectively assisting patients in managing pain with a reduction in the use of opioids, as compared to the current standard of care, HTX-011 could provide Heron with an additional platform to realize continued growth in the future.

“We believe that HTX-011 has the potential to meet our core goal of developing best-in-class medicines with the potential to significantly improve the lives of patients,” continued Quart.

For prospective investors, Heron’s rapid progress toward the commercialization of its two leading drug candidates could provide a platform to realize substantial returns in the years to come.

For more information, visit www.herontx.com